Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 66.44M | 37.14M | 15.02M | 22.29M | 17.32M |
Gross Profit | 50.95M | 27.20M | 7.51M | 12.46M | 3.56M |
EBITDA | 10.38M | 5.09M | 1.90M | 2.76M | 2.30M |
Net Income | 6.96M | 3.63M | 1.31M | 2.03M | 1.59M |
Balance Sheet | |||||
Total Assets | 25.55M | 17.64M | 14.27M | 12.04M | 11.63M |
Cash, Cash Equivalents and Short-Term Investments | 19.02M | 13.83M | 10.46M | 8.85M | 8.41M |
Total Debt | 123.86K | 478.59K | 104.57K | 79.01K | 32.00K |
Total Liabilities | 4.23M | 3.06M | 2.88M | 1.93M | 3.78M |
Stockholders Equity | 21.32M | 14.58M | 11.39M | 10.11M | 7.85M |
Cash Flow | |||||
Free Cash Flow | 5.73M | 3.91M | 1.89M | 237.42K | 2.88M |
Operating Cash Flow | 6.14M | 4.01M | 1.90M | 253.53K | 2.97M |
Investing Cash Flow | -441.17K | -101.78K | -13.18K | -16.12K | -91.20K |
Financing Cash Flow | -582.45K | -761.72K | -277.36K | 5.44M | -122.25K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | AU$98.12M | 10.12 | 45.86% | 1.70% | 71.65% | 152.89% | |
65 Neutral | ¥342.43B | 8.69 | -3.93% | 2.47% | 11.18% | -19.47% | |
― | $55.48M | ― | -41.60% | ― | ― | ― | |
― | $54.47M | ― | -99.05% | ― | ― | ― | |
― | $84.00M | ― | -154.88% | ― | ― | ― | |
55 Neutral | AU$109.89M | ― | ― | ― | -33.01% | ||
40 Underperform | AU$118.95M | ― | -85.35% | ― | 315.11% | 51.16% |
EZZ Life Science Holdings Ltd. has reported significant growth and strategic advancements in its quarterly activity report for Q4 FY25. The company successfully launched its EZZDAY brand in the United States, expanded its Southeast Asia distribution through a new agreement with ROFA Enterprises, and increased its presence in Australian pharmacies via a partnership with Direct Chemist Outlet. EZZ also engaged the University of Sydney for research on bone health supplements and reported strong financial performance with a 46% increase in customer receipts and a positive cash inflow. These developments position EZZ to capitalize on the growing demand for health supplements and maintain its competitive edge in the global health and wellness sector.
EZZ Life Science Holdings Ltd. has released a presentation document outlining its current position and future outlook. The document emphasizes the company’s caution regarding forward-looking statements and advises investors to conduct their own assessments. This release highlights the company’s commitment to transparency and careful communication with its stakeholders, reflecting a strategic approach to managing investor relations and market expectations.
EZZ Life Science Holdings Limited has launched its US-focused brand, EZZDAY, marking a significant step in its international expansion strategy. The launch includes FDA-registered health supplements tailored for the US market, supported by local manufacturing to meet consumer preferences and ensure supply chain resilience. The company has initiated sales through a Shopify store, with plans to expand to Amazon and engage in influencer marketing to boost brand awareness. This strategic entry into the US, one of the largest health supplement markets, aims to establish a sustainable presence and capitalize on the growing demand in key health categories.
EZZ Life Science Holdings Ltd. has announced a dividend distribution of AUD 0.02 per ordinary fully paid share, covering the six-month period ending December 31, 2024. The ex-dividend date is set for May 16, 2025, with the record date on May 19, 2025, and payment scheduled for June 17, 2025. This announcement reflects the company’s financial health and commitment to returning value to shareholders, potentially strengthening its market position and investor confidence.
EZZ Life Science Holdings Limited has announced a fully franked interim dividend of $0.020 per share for the half year ending 31 December 2024. This decision reflects the company’s commitment to rewarding shareholders and may enhance investor confidence. The dividend will be paid on 17 June 2025, with the ex-dividend date set for 16 May 2025 and the record date on 19 May 2025.